Mediclinic’s share price has fallen 36% in just over year, with the healthcare group facing regulatory headwinds which has constrained earnings and profits in some of its most lucrative and fastest growing markets. A recent Zurich regulatory ruling has offers positive news for the Swiss market outlook. Aslam Dalvi comments.
view article